Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics to Participate in Biotech Showcase 2020

PARIS and NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug...
December 09, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics and Biolab Sanus Pharmaceutical Enter into Exclusive Licensing and Collaboration Agreement for Firibastat in Latin America

PARIS and NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly...
October 07, 2019 01:30 ET | Source: Quantum Genomics

Quantum Genomics Enters Into Exclusive Negotiations for its First Partnership

PARIS and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug...
October 03, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update

Arterial hypertension: preparing for the pivotal Phase III study of firibastat in patients with resistant arterial hypertension Heart failure: the first patients were enrolled in June in...
September 11, 2019 13:34 ET | Source: Quantum Genomics

Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure

PARIS and NEW YORK, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that a...
September 02, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension

PARIS and NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
July 03, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics Selected to Enter the European Rising Tech Label

PARIS and NEW YORK, July 03, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
June 27, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics Announces Result of Annual General Meeting

PARIS and NEW YORK, June 27, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical...
June 12, 2019 12:00 ET | Source: Quantum Genomics

A key milestone reached by Quantum Genomics in the development of firibastat

A novel 500 mg controlled-release tablet of firibastat offering an optimal pharmacokinetic profile for once-a-day dosing has been identified PARIS and NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) --...
June 06, 2019 12:00 ET | Source: Quantum Genomics

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat in Heart Failure Patients

PARIS and NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...